Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus neoadjuvant chemotherapy for advanced epithelial ovarian cancer
ChiCTR2400088038Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of bevacizumab in epithelial ovarian cancer (EOC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Chemotherapy response score 3. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
bevacizumab
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on ChiCTR2400088038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088038.